Related Experiment Videos
Second generation knockout sickle mice: the effect of HbF.
M E Fabry1, S M Suzuka, R S Weinberg
1Departments of Medicine and Pathology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA. fabry@aecom.yu.edu
Blood
|January 12, 2001
Summary
New sickle cell mice models show that increasing fetal hemoglobin (HbF) levels significantly reduces disease severity. These mice are valuable for testing gene therapies and understanding sickle cell disease pathology.
Area of Science:
- Hematology
- Genetics
- Disease Modeling
Background:
- Sickle cell disease (SCD) research requires animal models with faithful pathology.
- Transgenic mice expressing human sickle hemoglobin (HbS) are crucial for studying SCD and evaluating gene therapies.
- These models must exhibit significant SCD pathology and demonstrate amelioration with antisickling agents.
Purpose of the Study:
- To develop and characterize novel transgenic mouse models of sickle cell disease.
- To investigate the impact of varying levels of fetal hemoglobin (HbF) on SCD pathology in mice.
- To establish a reliable platform for testing gene therapy strategies for SCD.
Main Methods:
- Generation of transgenic mice with exclusively human sickle hemoglobin (HbS) and varying levels of HbF.
- Utilizing mouse alpha- and beta-globin knockouts alongside human gamma-transgenes.
- Assessment of hematocrit, reticulocyte count, urine concentrating ability, and histopathology.
Main Results:
- Mice exhibited balanced globin chain synthesis and near-normal mean corpuscular hemoglobin.
- Progressive increase in HbF (3% to 40%) correlated with improved hematocrit and reduced reticulocyte counts.
- Elevated HbF normalized urine concentrating ability and ameliorated tissue damage and organ weight.
Conclusions:
- Knockout mice expressing the miniLCRalpha2beta(S) transgene with postnatal HbF show accurate sickle cell pathology.
- These mice serve as a robust platform for evaluating antisickling interventions and gene therapies.
- The level of HbF required for amelioration varies between different transgenic SCD mouse models.